Portal de Periódicos da CAPES

Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-Up

2022; Lippincott Williams & Wilkins; Volume: 208; Issue: 1 Linguagem: Inglês

10.1097/ju.0000000000002758

1527-3792

James A. Eastham, Gregory B. Auffenberg, Daniel A. Barocas, Roger Chou, Tony Crispino, John W. Davis, Scott E. Eggener, Eric M. Horwitz, Christopher J. Kane, Erin Kirkby, Daniel W. Lin, Sean McBride, Alicia K. Morgans, Phillip M. Pierorazio, George Rodrigues, William W. Wong, Stephen A. Boorjian,

Health Systems, Economic Evaluations, Quality of Life

The summary presented herein represents Part II of the three-part series dedicated to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing principles of active surveillance and surgery as well as follow-up for patients after primary treatment. Please refer to Parts I and III for discussion of risk assessment, staging, and risk-based management (Part I), and principles of radiation and future directions (Part III).The systematic review utilized to inform this guideline was conducted by an independent methodological consultant. A research librarian conducted searches in Ovid MEDLINE, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews. The methodology team supplemented searches of electronic databases with the studies included in the prior AUA review and by reviewing reference lists of relevant articles.The Clinically Localized Prostate Cancer Panel created evidence- and consensus-based guideline statements to aid clinicians in the management of patients with clinically localized prostate cancer. Statements regarding active surveillance, surgical management, and patient follow-up are detailed.This guideline aims to inform clinicians treating patients with clinically localized prostate cancer. Continued research and publication of high-quality evidence from future trials will be essential to further improve care for these men.